Skip to main content

Advertisement

SpringerLink
Log in

Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside

  • Review
  • Published:
Seminars in Immunopathology Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and seventh in women, accounting for 7 % of all cancers, and the third cause of cancer-related death worldwide. Nearly 90 to 95 % of all HCC occur in the context of known and often preventable risk factors, such as chronic viral hepatitis, alcohol abuse, and metabolic disorders. Although several experimental lines of research support a direct role for hepatitis C virus (HCV) in cancer promotion, cirrhosis is the main risk factor for this tumor, whereas other factors like alcohol and tobacco smoking are clearly able to accelerate HCC development. For this reason, cirrhotic patients with chronic HCV infection are subjected to abdominal ultrasound surveillance every 6 months, aimed at an early diagnosis of HCC to allow curative treatment options. Current strategies to positively impact on HCC incidence rates in HCV patients include prevention of cirrhosis development by avoiding metabolic, pharmacological, or social factors associated with accelerated progression of liver disease, or through virus eradication by interferon-based treatments. Moreover, a successful antiviral treatment has the added benefit of positively impacting on the rate of HCC development also in patients who are already cirrhotic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5(9):558–567

    Article  PubMed  Google Scholar 

  2. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M (2006) The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43(6):1303–1310

    Article  PubMed  Google Scholar 

  3. Bralet MP, Régimbeau JM, Pineau P et al (2000) Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 32:200–204

    Article  PubMed  CAS  Google Scholar 

  4. El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127(5 Suppl 1):S27–S34

    Article  PubMed  Google Scholar 

  5. Kanwal F, Hoang T, Kramer JR et al (2011) Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 140(4):1182–1188

    Article  PubMed  Google Scholar 

  6. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C (2008) Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology 48(1):137–145

    Article  PubMed  Google Scholar 

  7. Bosch FX, Ribes J, Cléries R et al (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9:191–211

    Article  PubMed  Google Scholar 

  8. Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 Suppl 1):S5–S16

    Article  PubMed  Google Scholar 

  9. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5 Suppl 1):S35–S50

    Article  PubMed  Google Scholar 

  10. Benvegnù L, Gios M, Boccato S, Alberti A (2004) Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53(5):744–749

    Article  PubMed  Google Scholar 

  11. Tanaka Y, Hanada K, Mizokami M et al (2002) A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 99:15584–15589

    Article  PubMed  CAS  Google Scholar 

  12. Umemura T, Ichijo T, Yoshizawa K et al (2009) Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 44(suppl 19):102–107

    Google Scholar 

  13. Mizokami M, Tanaka Y (2005) Tracing the evolution of hepatitis C virus in the United States, Japan, and Egypt by using the molecular clock. Clin Gastroenterol Hepatol 3(10 Suppl 2):S82–S85

    Article  PubMed  Google Scholar 

  14. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138(2):513–521

    Article  PubMed  Google Scholar 

  15. Levrero M (2006) Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25(27):3834–3847

    Article  PubMed  CAS  Google Scholar 

  16. McGivern DR, Lemon SM (2011) Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 30(17):1969–1983

    Article  PubMed  CAS  Google Scholar 

  17. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD, HALT-C Trial Group (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136(1):138–148

    Article  PubMed  CAS  Google Scholar 

  18. Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S (2009) Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 15(5):578–582

    Article  PubMed  Google Scholar 

  19. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P (2009) Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 50(6):1142–1154

    Article  PubMed  CAS  Google Scholar 

  20. Houghton M (2009) The long and winding road leading to the identification of the hepatitis C virus. J Hepatol 51(5):939–948

    Article  PubMed  CAS  Google Scholar 

  21. Tardif KD, Mori K, Siddiqui A (2002) Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J Virol 76(15):7453–7459

    Article  PubMed  CAS  Google Scholar 

  22. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4(9):1065–1067

    Article  PubMed  CAS  Google Scholar 

  23. Naas T, Ghorbani M, Alvarez-Maya I, Lapner M, Kothary R, De Repentigny Y, Gomes S, Babiuk L, Giulivi A, Soare C, Azizi A, Diaz-Mitoma F (2005) Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol 86(Pt 8):2185–2196

    Article  PubMed  CAS  Google Scholar 

  24. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA, Lemon SM (2002) Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122(2):352–365

    Article  PubMed  CAS  Google Scholar 

  25. Machida K, Tsukamoto H, Mkrtchyan H et al (2009) Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A 106(5):1548–1553

    Article  PubMed  CAS  Google Scholar 

  26. Alter MJ, Kruszon-Moran D, Nainan OV et al (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341(8):556–562

    Article  PubMed  CAS  Google Scholar 

  27. Wiese M, Grüngreiff K, Güthoff W et al (2005) Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany—a 25-year multicenter study. J Hepatol 43(4):590–598

    Article  PubMed  Google Scholar 

  28. Vogt M, Lang T, Frösner G et al (1999) Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 341(12):866–870

    Article  PubMed  CAS  Google Scholar 

  29. Rumi MG, De Filippi F, La Vecchia C et al (2005) Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 54(3):402–406

    Article  PubMed  CAS  Google Scholar 

  30. Yu MW, Chen CJ (1993) Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 53(4):790–794

    PubMed  CAS  Google Scholar 

  31. Naugler WE, Sakurai T, Kim S et al (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317(5834):121–124

    Article  PubMed  CAS  Google Scholar 

  32. Brunetto MR, Oliveri F, Colombatto P, Bonino F (1995) Hepatocellular carcinoma and infections with multiple hepatitis viruses. Princess Takamatsu Symp 25:61–66

    PubMed  CAS  Google Scholar 

  33. Puoti M, Rossotti R, Garlaschelli A, Bruno R (2011) Hepatocellular carcinoma in HIV hepatitis C virus. Curr Opin HIV AIDS 6(6):534–538

    Article  PubMed  Google Scholar 

  34. Pollicino T, Squadrito G, Cerenzia G et al (2004) Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126(1):102–110

    Article  PubMed  CAS  Google Scholar 

  35. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D (1997) Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 26(2):485–490

    Article  PubMed  CAS  Google Scholar 

  36. Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31(4):339–346

    Article  PubMed  CAS  Google Scholar 

  37. Imbeaud S, Ladeiro Y, Zucman-Rossi J (2010) Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 30(1):75–86

    Article  PubMed  CAS  Google Scholar 

  38. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6(9):674–687

    Article  PubMed  CAS  Google Scholar 

  39. Nault JC, Zucman-Rossi J (2011) Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 31(2):173–187

    Article  PubMed  CAS  Google Scholar 

  40. Laurent-Puig P, Legoix P, Bluteau O et al (2001) Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120(7):1763–1773

    Article  PubMed  CAS  Google Scholar 

  41. Boyault S, Rickman DS, de Reyniès A et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45(1):42–52

    Article  PubMed  CAS  Google Scholar 

  42. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A et al (2010) New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 16(19):4688–4694

    Article  PubMed  CAS  Google Scholar 

  43. Toffanin S, Hoshida Y, Lachenmayer A et al (2011) MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 140(5):1618–1628

    Article  PubMed  CAS  Google Scholar 

  44. Breuhahn K, Gores G, Schirmacher P (2011) Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology 53(6):2112–2121

    Article  PubMed  Google Scholar 

  45. Roncalli M, Terracciano L, Di Tommaso L et al (2011) Liver precancerous lesions and hepatocellular carcinoma: the histology report. Dig Liver Dis 43(Suppl 4):S361–S372

    Article  PubMed  Google Scholar 

  46. Fasani P, Sangiovanni A, De Fazio C et al (1999) High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 29(6):1704–1707

    Article  PubMed  CAS  Google Scholar 

  47. Llovet JM, Bustamante J, Castells A et al (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29(1):62–67

    Article  PubMed  CAS  Google Scholar 

  48. Kumada T, Nakano S, Takeda I et al (1997) Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25(1):87–92

    Article  PubMed  CAS  Google Scholar 

  49. Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430

    Article  PubMed  CAS  Google Scholar 

  50. Llovet JM, Chen Y, Wurmbach E et al (2006) A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131(6):1758–1767

    Article  PubMed  CAS  Google Scholar 

  51. Marquardt JU, Galle PR, Teufel A (2012) Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol 56(1):267–275

    Article  PubMed  Google Scholar 

  52. Bruix J, Reig M, Rimola J et al (2011) Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 54(6):2238–2244

    Article  PubMed  Google Scholar 

  53. Sheu JC, Chen DS, Sung JL et al (1985) Hepatocellular carcinoma: US evolution in the early stage. Radiology 155(2):463–467

    PubMed  CAS  Google Scholar 

  54. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699

    Article  PubMed  CAS  Google Scholar 

  55. Takayama T, Makuuchi M, Hirohashi S et al (1998) Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 28(5):1241–1246

    Article  PubMed  CAS  Google Scholar 

  56. Kojiro M, Roskams T (2005) Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 25(2):133–142

    Article  PubMed  Google Scholar 

  57. Llovet J, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338

    Article  PubMed  CAS  Google Scholar 

  58. Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 56:918–928

    Article  PubMed  CAS  Google Scholar 

  59. Chevret S, Trinchet JC, Mathieu D et al (1999) A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 31:133–141

    Article  PubMed  CAS  Google Scholar 

  60. CLIP group (Cancer of the Liver Italian Program) (1998) Tamoxifen in the treatment of hepatocellular carcinoma: a randomized controlled trial. Lancet 352:17–20

    Article  Google Scholar 

  61. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL et al (2002) Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94:1760–1769

    Article  PubMed  Google Scholar 

  62. Sobin LH, Gospodarowicz MK, Wittekind Ch (eds) (2009) TNM classification of malignant tumors, 7th edn. Wiley, Oxford, pp 110–113

    Google Scholar 

  63. Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38:207–215

    Article  PubMed  Google Scholar 

  64. Tateishi R, Yoshida H, Shiina S et al (2005) Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54:419–425

    Article  PubMed  CAS  Google Scholar 

  65. Ganne-Carrié N, Chastang C, Chapel F et al (1996) Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 23:1112–1118

    Article  PubMed  Google Scholar 

  66. Velázquez RF, Rodríguez M, Navascués CA et al (2003) Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37(3):520–527

    Article  PubMed  Google Scholar 

  67. Sangiovanni A, Del Ninno E, Fasani P et al (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126(4):1005–1014

    Article  PubMed  Google Scholar 

  68. Kurosaki M, Hiramatsu N, Sakamoto M et al (2012) Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. J Hepatol 56(3):602–608

    Article  PubMed  Google Scholar 

  69. Masuzaki R, Tateishi R, Yoshida H et al (2009) Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 49(6):1954–1961

    Article  PubMed  Google Scholar 

  70. Ripoll C, Groszmann RJ, Garcia-Tsao G et al (2009) Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 50(5):923–928

    Article  PubMed  Google Scholar 

  71. Galmozzi E, Colombo M (2012) Genetic testing for hepatocellular carcinoma: an ambitious goal still to achieve. J Hepatol 56(6):1415–1416

    Article  PubMed  Google Scholar 

  72. Ge D, Fellay J, Thompson AJ, Simon JS et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401

    Article  PubMed  CAS  Google Scholar 

  73. Clifford RJ, Zhang J, Meerzaman DM et al (2010) Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology 52(6):2034–2043

    Article  PubMed  CAS  Google Scholar 

  74. Kumar V, Kato N, Urabe Y et al (2011) Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 43(5):455–458

    Article  PubMed  CAS  Google Scholar 

  75. Abu Dayyeh BK, Yang M, Fuchs BC et al (2011) A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 141(1):141–149

    Article  PubMed  CAS  Google Scholar 

  76. Hoshida Y, Villanueva A, Kobayashi M et al (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359(19):1995–2004

    Article  PubMed  CAS  Google Scholar 

  77. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM (2010) Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 30(1):35–51

    Article  PubMed  CAS  Google Scholar 

  78. Hino K, Okita K (2004) Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. J Antimicrob Chemother 53:19–22

    Article  PubMed  CAS  Google Scholar 

  79. Imai Y, Kawata S, Tamura S et al (1998) Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 129:94–99

    PubMed  CAS  Google Scholar 

  80. Yoshida H, Shiratori Y, Moriyama M et al (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174–181

    PubMed  CAS  Google Scholar 

  81. Tanaka H, Tsukuma H, Kasahara A et al (2000) Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 87:741–749

    Article  PubMed  CAS  Google Scholar 

  82. Ikeda K, Saitoh S, Arase Y et al (1999) Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,346 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124–1130

    Article  PubMed  CAS  Google Scholar 

  83. Shiratori Y, Ito Y, Yokosuka O et al (2005) Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142:105–114

    PubMed  CAS  Google Scholar 

  84. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G et al (2007) Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study 3. Hepatology 45:579–587

    Article  PubMed  CAS  Google Scholar 

  85. Yoshida H, Tateishi R, Arakawa Y et al (2004) Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 53:425–430

    Article  PubMed  CAS  Google Scholar 

  86. Yu ML, Lin SM, Lee CM et al (2006) A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 44:1086–1097

    Article  PubMed  CAS  Google Scholar 

  87. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC et al (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359(23):2429–2441

    Article  PubMed  Google Scholar 

  88. Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ et al (2011) Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 140(7):1990–1999

    Article  PubMed  CAS  Google Scholar 

  89. Afdhal N, Levine R, Brown R Jr, et al (2008) Colchicine versus peginterferon alfa 2b long-term therapy: results of the 4 year COPILOT trial (oral presentation). Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23–27; Milan, Italy

  90. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK et al (2011) Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 140(3):840–849

    Article  PubMed  CAS  Google Scholar 

  91. Aghemo A, Colombo M (2012) Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: the plot thickens. J Hepatol 56(1):276–278

    Article  PubMed  Google Scholar 

  92. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022

    Article  PubMed  Google Scholar 

  93. Aghemo A, Colombo M (2011) A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. Gastroenterology 141(1):396–399

    Article  PubMed  Google Scholar 

Download references

Financial disclosure

Alessio Aghemo has been a speaker and teacher at Roche, and has received travel support from Gilead, Bayer, Bristol-Myers Squibb, and Roche. Massimo Colombo has received grant and research support from Schering-Plough, Roche, Bristol-Myers Squibb, Gilead, and Bayer. He is also a member of the Advisory Board of Schering-Plough, Roche, Novartis, Vertex, Bristol-Myers Squibb, Gilead, Bayer, and Tibotec. Moreover, he has been a speaker and teacher at Schering-Plough, Roche, Novartis, Vertex, Bristol-Myers Squibb, Gilead, and Bayer.

Author information

Authors and Affiliations

  1. AM e A Migliavacca Center for Liver Disease, Department of Medicine, First Division of Gastroenterology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy

    Alessio Aghemo

  2. First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Via F. Sforza 35, 20122, Milan, Italy

    Massimo Colombo

Authors
  1. Alessio Aghemo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massimo Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Colombo.

Additional information

This article is published as part of the Special Issue on Immunopathology of viral hepatitis…

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aghemo, A., Colombo, M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 35, 111–120 (2013). https://doi.org/10.1007/s00281-012-0330-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00281-012-0330-z

Keywords

Search

Navigation